Polymorphisms of UDP-glucuronosyltransferase and pharmacokinetics of irinotecan

Therapeutic Drug Monitoring

Volumn 24, Issue 1, 2002, Pages 111-116

  Ando, Yuichi ^a   Ueoka, Hiroshi ^a   Sugiyama, Toru ^a   Ichiki, Masao ^a   Shimokata, Kaoru ^a   Hasegawa, Yoshinori ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Irinotecan; Pharmacogenetics; Pharmacokinetics; Polymorphism; UDP glucuronosyltransferase

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; 7 ETHYL 10 HYDROXYCAMPTOTHECIN GLUCURONIDE; CARBOPLATIN; CISPLATIN; DRUG METABOLITE; GLUCURONOSYLTRANSFERASE; IFOSFAMIDE; IRINOTECAN; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; CANCER; CANCER COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; DIARRHEA; DRUG GLUCURONIDATION; DRUG HYDROLYSIS; DRUG TRANSFORMATION; ENZYME ACTIVITY; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; PHARMACOGENETICS; PRIORITY JOURNAL; STATISTICAL DISTRIBUTION;

ADULT; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AREA UNDER CURVE; BILIRUBIN; CAMPTOTHECIN; ENZYME INHIBITORS; FEMALE; GLUCURONATES; GLUCURONOSYLTRANSFERASE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; POLYMORPHISM, GENETIC;

EID: 0036148810     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200202000-00018     Document Type: Conference Paper

References (27)

1. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11)
2. Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer
3. Phase I study and pharmacokinetics of CPT-11 with 5-day continuous infusion
4. Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials
5. Phases I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy
6. Pharmacokinetic, metabolic, and pharmacodynamic profiles in a dose-escalating study of irinotecan and cisplatin
7. Pharmacokinetic interrelationships of irinotecan (CPT-11) and its three major plasma metabolites in patients enrolled in phase I/II trials
8. Combination of oxaliplatin plus irinotecan in patients with gastrointestinal tumors: Results of two independent phase I studies with pharmacokinetics
9. Genetic predisposition to the metabolism of irinotecan (CPT-11): Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes
10. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: A pharmacogenetic analysis
11. UGT1a1 genotyping correlates with toxicity and survival in non-small-cell lung cancer (NSCLC) patients treated with second-line CPT-11/docetaxel
12. UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan
13. The UDP glycosyltransferase gene superfamily: Recommended nomenclature update based on evolutionary divergence
14. Bilirubin metabolism and hyperbilirubinemia
15. The genetic basis of the reduced expression of bilirubin UDP-glucuronosylgtansferase 1 in Gilbert's syndrome
16. Phase II study of irinotecan and cisplatin as first-line chemotherapy in advanced or recurrent cervical cancer
17. Phase I study of a combination of irinotecan and ifosfamide in advanced primary lung cancer
18. Phase I/II and pharmacological study of irinotecan and carboplatin for patients with lung cancer
19. Fractionated administration of irinotecan and cisplatin for treatment of lung cancer: A phase I study
20. Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse
21. Contribution of two missense mutations (G71R and Y486D) of the bilirubin UDP-glycosyltransferase (UGT1AI) gene to phenotypes of Gilbert's syndrome and Crigler-Najjar syndrome type II
22. Japanese clinical statistical data of patients with constitutional jaundice
23. Does Gilbert's disease exist?
24. The UGT1A1*28 allele relatively rare in a Japanese population
25. Irinotecan therapy in adults with recurrent to progressive malignant glioma
26. Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38) by the human UDP-glucuronosyltransferases encoded at the UGT1 locus
27. Genetic polymorphisms of UDP-glucuronosyltransferase (UGT) 1A7 gene and irinotecan toxicity in Japanese cancer patients